$JNJ · Johnson & Johnson

Johnson & Johnson filed its quarterly report on Form 10-Q for the fiscal quarter ended September 27, 2026. The filing covers the three and nine months ended September 27, 2026, and includes comparative financial information for the corresponding periods of fiscal 2025. The report presents consolidated financial statements and accompanying notes.

The extracted portion references Johnson & Johnson’s two business segments, Innovative Medicine and MedTech, as well as details on intangible assets, outstanding debt instruments, and derivative and hedging activities. These hedging activities include interest rate swaps, foreign exchange contracts, and cross-currency interest rate contracts.

The available text consists mainly of XBRL tagging data and does not contain a specific narrative announcement of financial results such as revenue, net income, or earnings per share. No other headline event is stated in the provided extract.